Kodiak Sciences reported a double Phase 3 win for its wet age-related macular degeneration candidates, saying the Phase 3 primary endpoints were met versus Regeneron’s Eylea (aflibercept). The company highlighted Zenkuda (tarcocimab tedromer) and the bispecific KSI-501 (tabirafusp-alpha-tedromer) achieving noninferiority for vision gains as part of the Daybreak program, a result that reshapes Kodiak’s approval strategy around longer dosing intervals.